SNHG1 (Small Nucleolar RNA Host Gene 1)

These findings highlight the value of combining competing endogenous RNA regulatory networks with nanomaterial based targeted delivery systems for GC therapy. The CLip@Sil platform offers a promising direction for the future development of precise and biomimetic nanotherapeutics in oncology.

In conclusion, our data highlight that PCa-derived exosomes-loaded SNHG1 mediated osteogenesis through the SNHG1/YBX1/MMP16 axis. SNHG1 may serve as a potential diagnostic marker and therapeutic target for bone metastasis in PCa.

The combined four-gene model demonstrated moderate discriminatory power, yielding an AUC of 0.76 (95 % CI 0.65-0.86, p < 0.0001) with balanced sensitivity and specificity of 69.8 % each at the 0.5 cutoff (overall accuracy 69.8 %). Taken together, RUSC1-AS1, SNHG17, PABPC1L and SNHG1 can be novel candidates for future diagnostic studies in CRC.

Several small nucleolar RNAs were found to be dysregulated in breast cancer specimens, supporting their further evaluation as potential biomarkers. In particular, SCARNA2, SNORD94, SNORD15B, SCARNA3, and RNU2-1 snRNA merit further investigation to determine their clinical relevance and biological roles in breast cancer.

SNHG11 could diagnose AML from healthy controls and related to poor prognosis of AML patients. SNHG11 could impact cell biology through miR-122-5p.

Taken together, our results indicated that WS treatment modulated several differentially expressed lncRNAs with putative regulatory potential in various neurodegenerative disorders. To the best of our knowledge, the lncRNA regulome that elicits the health-beneficial effects of WS has not been delineated thus far.

The influence of these regulatory RNAs on the main processes of ovarian oncogenesis, such as apoptosis, epithelial-mesenchymal transition, cell cycle control, and DNA methylation mechanisms in this type of cancer is considered. The prospects for clinical application of regulatory RNAs due to their influence on the level of drug resistance are also discussed.

Antisense oligonucleotides, small molecule inhibitors, and RNA interference are some of the strategies currently being investigated to dislodge the interactions between lncRNAs and histone-modifying enzymes, and they represent novel strategies for cancer therapy. This review summarizes recent advances in understanding lncRNA-histone modification crosstalk and its translation to the clinic for precision oncotherapy.

Pharmacological interventions targeting autophagy (Rapamycin) and Notch signaling (DAPT) further confirmed that SNHG1's effects on EMT are mediated via modulation of the autophagy-Notch1 interplay...Additionally, SNHG1 expression was significantly elevated in patients who progressed to low- or high-grade dysplasia, as confirmed by diagnostic endoscopic biopsies. Collectively, our study uncovers SNHG1 as a central molecular mediator linking acidic bile-induced EMT and autophagy regulation via the ULK1-Notch1 axis, highlighting its potential as a therapeutic target for preventing BE recurrence and progression to EAC.

Additionally, we observed increased expression of Slug, a key epithelial-mesenchymal transition (EMT) transcription factor, and decreased expression of its downstream target E-cadherin in Cd(II)-transformed cells. Collectively, these results demonstrate that elevated SNHG1 promotes the expression of Sox2, Rac1, and Slug, thereby driving the invasive and migratory behavior of Cd(II)-transformed cells.

RNA stability changes were evaluated by an actinomycin D assay...And SNHG1, promoted the transcription of WDR74 in cis, via recruitment of EWSR1, thereby facilitated WDR74-mediated proliferation and migration in OS cells. These findings provide new insights into the epigenetic regulation of OS and highlight potential therapeutic targets.

Therefore, this review aims to summarise the current investigations on the pathogenesis of SNHG1 in HCC, highlighting its potential as a molecular marker for early prediction and prognostic assessment. As a multifunctional modulator, SNHG1 is extensively involved in molecular signalling pathways in HCC progression and is valuable for therapeutic targeting.